Aditxt, Inc. (ADTX)
About Aditxt, Inc.
Aditxt Inc is a life sciences company that develops, builds, and grows innovations with a focus on monitoring and modulating the immune system. It develops products designed to induce tolerance to transplanted organs. Its portfolio consists of two programs Adimune and AditxtScore. It firm's immunosuppressive (anti-rejection) drugs have made possible life-saving organ transplantation procedures and blocking of unwanted immune responses in autoimmune diseases. It is also developing a technology called Apoptotic DNA Immunotherapy (ADi) ADI-100, which utilizes a novel approach that mimics, the way bodies naturally induce tolerance to tissues. The company operates in one segment, which is focused on the discovery and development of biopharmaceutical products.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $3.2K
- Net income
- -$43.1M
- Total assets
- $16.5M
- Market cap
- $50.7K
- Gross margin
- 8.4%
- Operating margin
- -612542.2%
- Net margin
- -1339187.6%
Source: SEC EDGAR · updated Jun 8, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $3.2K
- Cost of revenue
- $2.9K
- Gross profit
- $268
- Operating expenses
- $19.6M
- Operating income
- -$19.6M
- Net income
- -$42.8M
- EPS (basic)
- $-1,153.83
- EPS (diluted)
- $-1,153.83
Balance sheet
- Total assets
- $16.5M
- Current assets
- $3.8M
- Total liabilities
- $12.6M
- Current liabilities
- $12.2M
- Shareholders’ equity
- $4.0M
Cash flow
- Operating cash flow
- -$25.7M
- Investing cash flow
- -$2.4M
- Financing cash flow
- $30.5M
- Net cash flow
- $2.4M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $50.7K
- EPS (diluted)
- $-1153.83
- Shares outstanding
- 5.1M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jun 30, 2020
Aditxt, Inc. (ADTX) Stock Price
- Reported a net loss of $43.1M in FY2025.
- Revenue declined 97% from FY2021 to FY2025.
- Gross margin of 8.4%, net margin -1339187.6%.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Aditxt, Inc..
Write a review
News about Aditxt, Inc.
News & sentiment via Polygon.io
Aditxt, Inc.: frequently asked questions
Is Aditxt, Inc. an American company?
Aditxt, Inc. is a US-based company headquartered in Richmond, Virginia, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Where is Aditxt, Inc. headquartered?
Aditxt, Inc. is headquartered in Richmond, Virginia, United States.
Is Aditxt, Inc. publicly traded?
Yes — Aditxt, Inc. is a publicly traded company. Its stock trades under the ticker symbol ADTX on the NASDAQ.
What does Aditxt, Inc. do?
Aditxt, Inc. is an American Pharmaceuticals company in the Health & Beauty sector.
